IL1B and type 2 diabetes mellitus: It must be pointed out that by treating our patients with an anti-IL-1 agent, we were able to reach the optimal therapeutic targets for both RA and T2DM, thus decreasing their CVD risk according to the European League Against Rheumatism recommendations [9].